## **SUPPLEMENT DATED OCTOBER 15, 2020**



Bank of America Corporation U.S. \$65,000,000,000 Euro Medium-Term Note Program

This supplement (the "Supplement"), which supplements the Base Prospectus dated May 15, 2020 (the "Original Base Prospectus") (as supplemented by the Supplementary Base Prospectuses dated July 17, 2020 and August 3, 2020, the "Base Prospectus"), which together comprise a base prospectus for the purposes of Article 8 of Regulation (EU) 2017/1129 (the "Prospectus Regulation"), constitutes a supplementary prospectus for the purposes of Article 23 of the Prospectus Regulation and is prepared in connection with the U.S. \$65,000,000,000 Euro Medium-Term Note Program (the "Program") of Bank of America Corporation (the "Issuer"). Terms defined in the Base Prospectus have the same meaning when used in this Supplement.

This Supplement is supplemental to, and shall be read in conjunction with, the Base Prospectus. To the extent that there is any inconsistency between any statement in this Supplement and any other statement in or incorporated by reference into the Base Prospectus, the statements in this Supplement will prevail.

This Supplement has been approved by the United Kingdom Financial Conduct Authority (the "FCA"), as competent authority under the Prospectus Regulation. The FCA only approves this Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation and such approval should not be considered as an endorsement of the Issuer that is the subject of this Supplement.

The purpose of this Supplement is to incorporate by reference the Issuer's current report on Form 8-K dated October 14, 2020 (the "October 14, 2020 Form 8-K") in respect of the earnings press release relating to the nine months ended September 30, 2020.

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer, the information contained in this Supplement is in accordance with the facts and this Supplement makes no omission likely to affect its import.

Save as disclosed in this Supplement or in the document incorporated by reference into, and forming part of, this Supplement, no other significant new factor, material mistake or inaccuracy relating to information included in the Base Prospectus has arisen or been noted, as the case may be, since the publication of the Base Prospectus as supplemented from time to time.

## Incorporation by reference of the October 14, 2020 Form 8-K

The October 14, 2020 Form 8-K was filed with the United States Securities and Exchange Commission (the "SEC") on October 14, 2020 and with the FCA. The October 14, 2020 Form 8-K shall be deemed to be incorporated by reference into, and form part of, this Supplement other than the information under the headings "Item 7.01 Regulation FD Disclosure" (page 3\*), "Exhibit 99.2" (entitled "The Presentation Materials") (pages 23\* - 55\*) and "Exhibit 99.3" (entitled "The Supplemental Information") (pages 56\*-90\*) of the October 14, 2020 Form 8-K which shall not be deemed to be incorporated by reference into, or form part of, this Supplement. For the purposes of the Prospectus Regulation and this Supplement, any information or other documents incorporated by reference, either expressly or implicitly, into the October 14, 2020 Form 8-K, or not deemed to have been filed as part of the October 14, 2020 Form 8-K under the rules of the SEC, do not form part of this Supplement. Information in the October 14, 2020 Form 8-K which is not incorporated by reference into the Base Prospectus is either not relevant for the investor or is covered elsewhere in the Base Prospectus.

\*These page numbers are references to the PDF pages included in the October 14, 2020 Form 8-K.

## Documents available for inspection

The Issuer will provide, without charge, to each person to whom a copy of this Supplement has been delivered, upon the oral or written request of such person, a copy of the document incorporated herein by reference. Written requests for such document should be directed to: Bank of America Corporation, Bank of America Corporate

Center, 100 North Tryon Street, Charlotte, North Carolina 28255-0065, Attention: Fixed Income Investor Relations or <a href="mailto:fixedincomeir@bankofamerica.com">fixedincomeir@bankofamerica.com</a>. Telephone requests may be directed to +1-866-607-1234 (toll free) or +1-212-449-6795. The Issuer's filings with the SEC are available through (1) the SEC's website at <a href="https://www.sec.gov">www.sec.gov</a>, and (2) the Issuer's website at <a href="https://investor.bankofamerica.com/phoenix.zhtml?c=71595&p=irol-sec#fbid=vPBmqoqUe99">https://investor.bankofamerica.com/phoenix.zhtml?c=71595&p=irol-sec#fbid=vPBmqoqUe99</a>. This Supplement shall be available on or around the date hereof in electronic form at <a href="https://www.londonstockexchange.com/exchange/news/market-news/marketnews-home.html">https://www.londonstockexchange.com/exchange/news/market-news/marketnews-home.html</a>. Except as specifically incorporated by reference into this Supplement, information on these websites is not part of this Supplement.

This Supplement also supplements the Offering Circular dated May 15, 2020 for the purposes of Non-PR Notes admitted to trading on the ISM.